These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 163676)

  • 1. Yoshi 864 (NSC 102627) 1-propanol, 3, 3'-iminodi-dimethanesulfonate (ester) hydrochloride: a phase 1 study.
    Altman SJ; Fletcher WS; Andrews NC; Wilson WL; Pischer T
    Cancer; 1975 Apr; 35(4):1145-7. PubMed ID: 163676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors.
    Altman SJ; Metter GE; Nealon TF; Weiss AJ; Ramirez G; Madden RE; Fletcher WS; Strawitz JG; Multhauf PM
    Cancer Treat Rep; 1978 Mar; 62(3):389-95. PubMed ID: 206359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally.
    Hirano M; Miura M; Kakizawa H; Morita A; Uetani T; Ohno R; Kawashima K; Nishiwaki H; Yamada K
    Cancer Chemother Rep; 1972 Jun; 56(3):335-8. PubMed ID: 19051492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864).
    Drewinko B; Barlogie B
    Cancer Treat Rep; 1976 Nov; 60(11):1637-45. PubMed ID: 191191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of vincristine and alkylating agent No. 864 on rat leukemia in relation to the distribution of drugs and leukemic cells.
    Aoshima M; Sakurai Y
    Gan; 1973 Oct; 64(5):417-25. PubMed ID: 4358729
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix.
    Slavik M; Muss H; Blessing JA
    Cancer Treat Rep; 1983 Feb; 67(2):195-6. PubMed ID: 6297730
    [No Abstract]   [Full Text] [Related]  

  • 7. Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.
    Keyes JW; Selawry OS; Hansen HH
    Cancer Chemother Rep; 1971 Dec; 55(5):583-9. PubMed ID: 5003621
    [No Abstract]   [Full Text] [Related]  

  • 8. [Preliminary observations on the results of treating malignant lymphoma with Lycurim].
    Polubiec A; Kolakowska-Polubiec K; Mariańska B; Perzanowska I
    Acta Haematol Pol; 1977; 8(3):213-9. PubMed ID: 200051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of methylene dimethane sulfonate.
    Smith DB; Fox BW; Thatcher N; Steward WP; Scarffe JH; Wagstaff J; Vezin R; Crowther D
    Cancer Treat Rep; 1987 Sep; 71(9):817-20. PubMed ID: 3621213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
    Smith DB; Lind MJ; Kaye SB; Newlands ES; Blackledge GR; Gibson A
    Br J Cancer; 1988 May; 57(5):512-3. PubMed ID: 3395557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.
    Phillips RW; Brook J
    Cancer Chemother Rep; 1971 Dec; 55(5):567-73. PubMed ID: 4946081
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
    Slavik M; Muss H; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Sep; 66(9):1775-7. PubMed ID: 6288239
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary pharmacological studies with 1,6-dimesyl-2,3-4,5-dianhydro-L-iditol in patients with cancer.
    Csetényi J; Bihari V; Számel SI; Horváth IP; Eckhardt S
    Eur J Cancer (1965); 1975 Sep; 11(9):675-6. PubMed ID: 176030
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of two new sulfonic acid esters of aminoglycols on chronic myelogenous leukemia.
    Hirano M; Miura M; Kakizawa H; Morita A; Uetani T
    Cancer Chemother Rep; 1972 Feb; 56(1):47-52. PubMed ID: 4503637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.